Bristol Myers Squibb Co. closed 1.88% below its 52-week high of $61.10, which the company reached on January 27th.

We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

Looking at Bristol-Myers Squibb Company's (NYSE:BMY ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by ...

Study urges industry to be more transparent and fairer in selecting speakers, and to recruit more women to steering ...

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...

Bristol Myers Squibb (BMY) is one of the stocks most watched ... Over the past month, shares of this biopharmaceutical company have returned +3.5%, compared to the Zacks S&P 500 composite's ...

The Union Budget 2025-26 introduces key healthcare measures, including the exemption of 36 life-saving drugs from Basic ...

Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at ...